Alzamend Neuro’s experimental oral therapy for dementia related to Alzheimer’s disease may deliver the benefits of marketed lithium-based treatments but with fewer side effects, data from a completed Phase 1 trial show. A 150 milligrams (mg) dose of the therapy, called AL001, led to similar levels of lithium in the blood as a 300 mg capsule of marketed lithium carbonate, according to the company. AL001 was found safe and well-tolerated in healthy participants, with no…
April 07, 2022April 7, 2022